Thanks.
As you know, Canada's Access to Medicines Regime is an important regime. The Government of Canada wants to meet the commitment it made to ensure that our country can be a world leader in the fight against public health problems in the developing countries and in the less advanced countries. We have made financial commitments in the last 2006 budget. The government will support programs like the World Fund for the Fight Against AIDS, Tuberculosis and Malaria and the Global Polio Eradication Initiative, and it has facilitated protection against the shocks that those diseases cause.
This funding that we provided in the last budget will assist programs in achieving their objectives with regard to devastating diseases in the hardest hit countries of the Third World. Those diseases kill nearly six million persons a year.
In putting in place Canada's Access to Medicines Regime, the Government of Canada has created a statutory framework for exporting pharmaceutical products at reduced prices to Third World countries. I wish to point out that the regime is part of the efforts that Canada is making to assert its values and interests on the international stage, by providing necessary aid to the least well-off countries coping with public health problems, AIDS, tuberculosis and so on.
Some have criticized the fact that from the moment it was implemented, the regime has not resulted in the export of medicines to the countries requesting them. In the next few weeks, we're going to start a review of the regime's provisions in order to establish and accelerate the export of Canadian medicines to developing countries, while honouring Canada's international obligations.
This access to medicines regime for developing countries must also be consistent with the statutory provisions on patent medicines. It must comply with the act. The first purpose of the act is to establish a balance between predictability and stability in Canadian regulation of intellectual property. As regards intellectual property in this field, the government and I, as Minister of Industry, want to reconcile the need for protection that will encourage timely research on more effective medicines with enhanced competition from generic products in order to reduce public health costs.